ST. LOUIS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ: ADV) announced the appointments of Thomas Turner and Xiaofeng "Frank" Yao to its Board of Directors, effective as of February 20, 2026. About Thomas Turner Turner currently serves as Senior Managing Director at CVC Capital Partners (U.S.) Inc., where he has been a member of the Capital Markets team since September 2022. Prior to CVC, Turner held Managing Director roles at Apollo Global Management, Inc. and Bank of America Merrill ...

IP and technology acquisition is expected to be highly accretive and to advance Lifeward’s position as a diversified biomedical innovation companyWill Expand Lifeward’s portfolio beyond lower-limb solutions, creating a differentiated, whole-body neuro-rehabilitation portfolio Will Strengthen long-term strategic networks with neuro-rehabilitation prescribers, rehabilitation networks, and payers HUDSON, Mass. and YOKNEAM ILLIT, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” ...

PRINCETON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate and present in TD Cowen’s 46th Annual Health Care Conference, t ...

BURLINGTON, Mass. and JERUSALEM, Feb. 25, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation technologies, today announced that it will report its fourth quarter and full year 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Wednesday, March 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results an ...

LONGBOAT KEY, FL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Rumble Inc. (NASDAQ:RUM), the Freedom-First technology platform, today announced that Rumble Shorts has been approved by the Apple App Store. This means iPhone users are now able to download or update their Rumble apps to experience Rumble Shorts on iOS.Rumble announced the debut of Rumble Shorts on the web at rumble.com/shorts earlier this month. Google Play already approved Rumble Shorts for Android phones, so Apple’s approval means Rumble Shorts is avai ...

Partnership will leverage Vivtex’s proprietary technologies built to identify optimal oral formulations for peptide and protein therapeutics with improved bioavailabilityNovo Nordisk will lead global development and commercialization, and Vivtex is eligible to receive up to 2.1 billion US dollars, as well as royalties on net sales of future productsPartnership expands Vivtex’s platform to metabolic diseases and supports Novo Nordisk’s mission to deliver scalable and innovative medicines to people with obesi ...

Core Insights - Tempest Therapeutics announced promising clinical data from the ongoing REDEEM-1 Phase 1/2a trial for TPST-2003, a dual-targeting CAR-T therapy for relapsed/refractory multiple myeloma [1][6] Clinical Data Summary - TPST-2003 is designed to enhance response depth and durability in patients with relapsed/refractory multiple myeloma through a dual-targeting CAR structure [2] - As of January 31, 2026, 36 patients with relapsed/refractory multiple myeloma have received TPST-2003, with a median of four prior lines of therapy [3] - All six evaluable patients in the REDEEM-1 trial achieved a complete response (CR), resulting in an overall response rate (ORR) of 100% among 25 evaluable patients [4][8] Safety Profile - TPST-2003 demonstrated a favorable safety profile across all dose levels, with no Grade >3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) reported [7][9] - The prior investigator-initiated trial (IIT) showed a median progression-free survival (PFS) of 23.1 months, including patients with extramedullary disease [8][10] Future Development Plans - Tempest plans to accelerate the development of TPST-2003 and intends to submit a U.S. IND application, aiming to initiate a U.S. registrational study in 2026 [6][15] - The company is also exploring the potential of TPST-2003 for treating large B-cell lymphoma and other related indications [6][12] Treatment Landscape - Approved CAR-T therapies have shown clinical benefits in relapsed/refractory multiple myeloma, but challenges such as relapse and toxicity management remain prevalent [13] - TPST-2003's dual-targeting CAR structure aims to address tumor heterogeneity and antigen escape, which are significant factors in disease progression [14]

Core Viewpoint - Ryman Hospitality Properties, Inc. plans to offer $700 million in senior notes due 2034 to refinance existing debt and strengthen its financial position [1][2]. Group 1: Offering Details - The company intends to issue $700 million in senior unsecured notes, which will be guaranteed by the company and its subsidiaries [1]. - The net proceeds from the offering will be used to fully redeem the existing 4.750% senior notes due 2027, including accrued interest and related fees [2]. Group 2: Regulatory Compliance - The notes will be offered only to qualified institutional buyers and certain non-U.S. persons, in compliance with Rule 144A and Regulation S under the Securities Act [3]. Group 3: Company Overview - Ryman Hospitality Properties, Inc. is a leading real estate investment trust specializing in upscale convention center resorts and entertainment experiences, managing a portfolio that includes five of the top seven largest non-gaming convention center hotels in the U.S. [5]. - The company owns a total of 12,364 hotel rooms and over 3 million square feet of meeting space across its properties [5]. - Ryman also holds a 70% controlling interest in Opry Entertainment Group, which includes iconic country music brands and manages various entertainment venues [5].

Core Viewpoint - Virtuix Inc. is advancing the field of full-body virtual reality systems through its Omni technology, which allows for natural movement in AI-generated environments, enhancing human-robot interaction and teleoperation capabilities [1][2][5]. Group 1: Collaboration and Technology - Virtuix has partnered with the University of Central Florida's Institute for Simulation & Training to demonstrate real-time control of humanoid robots using the Omni One omni-directional treadmill [2][4]. - The Omni One system enables operators to walk and move in any direction, allowing humanoid robots to mirror these movements, addressing limitations in teleoperation [4][5]. - The collaboration utilizes a stereoscopic "CAVE-like" projection system called vDen, which enhances operator comfort and spatial awareness without the need for head-mounted displays [5][6]. Group 2: Product Development - Virtuix is collaborating with 1HMX to develop the Nexus NX1, a full-body system designed for humanoid robot teleoperation and physical AI training [7]. - The NX1 integrates the Omni One treadmill with HaptX Gloves G1, providing lifelike tactile feedback and real-time sensory data to improve robot performance [7][8]. - This system aims to generate detailed movement data that can enhance the autonomy and capabilities of humanoid robots [8]. Group 3: Market Position and Vision - Virtuix positions itself as a leader in the full-body virtual reality market, catering to consumer, enterprise, and defense sectors with its innovative Omni technology [9]. - The company emphasizes the potential of its products in the growing field of humanoid robots and embodied AI, highlighting the importance of immersive VR technology in practical robotics applications [5][6].

Core Insights - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for various CNS disorders, including Alzheimer's disease and Parkinson's disease [1][3] - The company will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 [1] Company Overview - Anavex Life Sciences Corp. is publicly traded on Nasdaq under the ticker AVXL and is dedicated to developing novel therapeutics for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders [3] - The lead drug candidate, ANAVEX2-73 (blarcamesine), has completed multiple clinical trials for Alzheimer's disease and has shown potential in treating Parkinson's disease dementia and Rett syndrome [3] - ANAVEX2-73 is designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, with preclinical studies indicating its ability to halt or reverse Alzheimer's disease progression [3] - The company is also developing ANAVEX3-71, which targets SIGMAR1 and M1 muscarinic receptors, showing promise in addressing cognitive deficits and other hallmarks of Alzheimer's disease in preclinical trials [3]